Compare ARQQ & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | HELP |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.7M | 303.9M |
| IPO Year | N/A | N/A |
| Metric | ARQQ | HELP |
|---|---|---|
| Price | $16.53 | $6.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 270.7K | ★ 465.6K |
| Earning Date | 12-09-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $381.13 | N/A |
| Revenue Next Year | $212.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.00 | $4.81 |
| 52 Week High | $62.00 | $10.59 |
| Indicator | ARQQ | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 51.00 |
| Support Level | $15.89 | $5.88 |
| Resistance Level | $17.45 | $6.65 |
| Average True Range (ATR) | 1.57 | 0.59 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 7.34 | 70.13 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.